The reported efficacy of BCG vaccine in preventing pulmonary tuberculosis varies from 0-80%; however, its efficacy in preventing tuberculous meningitis ranges from 520/%-84%. A case-control study was conducted to assess the efficacy of BCG in preventing tuberculous meningitis in children. New cases oftuberculous meningitis, confirmed bacteriologically, were registered as cases. Controls were children suffering from febrile convulsions attending the same hospital. A total of 107 cases and 321 controls, block matched for age, were registered. Vaccination status was determined from the history reported by the mother and by BCG scar reading. Data regarding socioeconomic status, crowding, and nutritional status were collected. Using multiple logistic regression analysis the odds ratio obtained for the presence of BCG scar was 0-23 (95% confidence interval (CI) 0-14 to 0.37) and the protective efficacy of BCG vaccine in preventing tuberculous meningitis in children was found to be 77% (95% CI 71 to 83%).
Tuberculosis continues to be a widespread disease especially in developing countries. Tuberculous meningitis, a serious complication of this infection, occurs in 7-12% of patients with tuberculosis and it is more common in children. 1 In children, even with treatment, the mortality of tuberculous meningitis is 27% and permanent disability is estimated to be as high as 39%.2 BCG vaccination to control tuberculosis is still widely being used around the world, but 
Results
The age of the 107 patients ranged from 6 months to 12 years. The number of children under 5 years was 74 (69%), and boys constituted 63 (59%) of the total. The mothers of 75 (70%) of our cases never attended school. A large proportion of patients (78, 73%) were living in kutcha houses. The vast majority (94%) of cases and controls were living in houses with an area of less than 100 square feet. Cases and controls were comparable with respect to different characteristics (table 1) .
Among cases, the chest radiograph was normal in 71 (66%), pneumonitis was present in 18 (17%), bronchopneumonia was present in five (5%), and miliary tuberculosis in five (5%). Hilar adenitis or thickened pleura were seen in eight (7%) cases. Mantoux skin test was positive (> 10 mm) in 13% of cases. Acid fast bacilli were demonstrated in cerebrospinal fluid by culture alone in 93 (87%) cases, by smear alone in eight (7%) cases, and by both smear and culture in six (6%) cases.
The chance corrected agreement (K) for scar reading between the medical officer and the paramedical worker was 0.8. A BCG scar was present in 35 (33%) out of 107 cases and 219 (68%) out of 321 controls. From the mother's history, exposure to BCG vaccination was positive in 53 (50%) cases out of 107, and 259 (81%) controls out of 321. In 81 cases and 265 controls scar status and maternal history for BCG vaccination were in total agreement. Among this group, 31 (38%) out of 81 cases and 211 (80%) out of 265 controls had both a BCG scar and a positive maternal history for BCG vaccination.
The effect of BCG vaccine upon risk of development of tuberculous meningitis was estimated separately by univariate analysis and through multiple logistic regression analysis. When the BCG scar was taken as the measure of vaccination status, the OR was 0-23 (95% confidence interval (CI) 0.14 to 0 37) and the efficacy of BCG vaccine is poorly understood and needs to be evaluated further. Literacy of mothers appeared to be an important risk factor and this has to be assessed further in future studies. The OR for better house type was 0-52 but the OR for more living space per head was 1 64. These contradicting values could have been due to misclassification error as a result of the wrong estimation of living space. In the present study, type of house is a reliable parameter compared with living space per head as the latter involved the parent's judgment about space. The OR for BCG vaccination was not much different in the presence of other parameters for different regression models.
In case-control studies, case definition is very crucial. Earlier studies defined cases either clinically or used a combination of clinical and bacteriological criteria other than cerebrospinal fluid culture. However, this study used a more specific case diagnosis, demonstration of acid fast bacilli in cerebrospinal fluid, as the case definition of tuberculous meningitis, thus decreasing misclassification bias.
Another potential source of bias is the ascertainment of vaccination status. History of vaccination, without evidence of a scar, must be interpreted cautiously. Additionally, a BCG scar may disappear over time. In order to minimise this error, vaccination status was classified into two categories: definite exposure and probable exposure. The protective efficacy was almost similar in these two groups, 84% and 77% respectively, indicating that such a misclassification was less likely to have occurred in this study. Two more precautions were taken to minimise measurement error while identifying BCG scar. The paramedical worker who examined the children for BCG scar was unaware of the null hypothesis and the scar reading was carried out before cerebrospinal fluid culture results were available.
Ideal control subjects would have been neighbourhood controls. But, with the available limited resources, identifying and recruiting matched neighbourhood controls for cases coming from different parts of the state was a limiting factor. Hospital controls were more likely to have received BCG vaccine than neighbourhood controls. However, in this study the proportion of children who contacted the doctor at least once for other vaccinations like diphtheria, tetanus, and pertussis and oral polio virus were equal in cases and controls. Thus it appears that cases were comparable with controls with respect to opportunities for being vaccinated with BCG. Cases and controls were also similar with reference to age, sex, and crowding.
This study shows BCG vaccine to be 77% efficacious in preventing tuberculous meningitis in children. Regardless of the protective efficacy of BCG in preventing pulmonary tuberculosis, in areas in which tuberculosis affects a significant percentage of the population, continued use of BCG may be warranted to prevent tuberculous meningitis. 
